Anaptysbio Stock Today
| ANAB Stock | USD 51.21 0.67 1.33% |
PerformanceGood
| Odds Of DistressSmall
|
AnaptysBio is trading at 51.21 as of the 3rd of February 2026, a 1.33 percent increase since the beginning of the trading day. The stock's open price was 50.54. AnaptysBio has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 5th of November 2025 and ending today, the 3rd of February 2026. Click here to learn more.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 27.69 M outstanding shares of which 5.57 M shares are presently shorted by private and institutional investors with about 10.53 trading days to cover. More on AnaptysBio
Moving against AnaptysBio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
AnaptysBio Stock Highlights
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
AnaptysBio (ANAB) is traded on NASDAQ Exchange in USA and employs 136 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.33 B. AnaptysBio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.69 M outstanding shares of which 5.57 M shares are presently shorted by private and institutional investors with about 10.53 trading days to cover.
AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
Check AnaptysBio Probability Of Bankruptcy
Ownership AllocationThe majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company.
Check AnaptysBio Ownership Details
AnaptysBio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. AnaptysBio market risk premium is the additional return an investor will receive from holding AnaptysBio long position in a well-diversified portfolio.
| Mean Deviation | 2.68 | |||
| Semi Deviation | 3.7 | |||
| Standard Deviation | 3.83 | |||
| Variance | 14.65 |
AnaptysBio Stock Against Markets
AnaptysBio Corporate Management
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| David McKeon | Senior Controller | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile |
Already Invested in AnaptysBio?
The danger of trading AnaptysBio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AnaptysBio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AnaptysBio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AnaptysBio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive AnaptysBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that AnaptysBio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AnaptysBio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, AnaptysBio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.